Deuterated Droxidopa Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with norepinephrine deficiency, such as orthostatic hypotension, face challenges due to the rapid metabolism of norepinephrine and the formation of toxic metabolites, leading to side effects and compliance issues with existing medications like droxidopa, which has a short half-life and requires frequent dosing.
Innovation Solution
Deuterated droxidopa compounds are developed to slow down metabolism, increase half-life, and reduce toxic metabolite production, potentially offering a safer and more effective treatment option with extended-release formulations to manage norepinephrine levels effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If droxidopa is used to treat norepinephrine deficiency, then norepinephrine levels are increased, but the drug has a short half-life and requires frequent dosing
Solution Approach 1:
The patent applies parameter changes by deuterating specific carbon positions in the droxidopa molecule (positions 3, 4, 5, or 6 of the catechol ring). This isotopic substitution changes the physical-chemical parameters of the molecule, specifically slowing metabolic degradation through the kinetic isotope effect, thereby extending the half-life from minutes to hours while maintaining the drug's ability to increase norepinephrine levels.
2Reliability
If droxidopa is administered to increase norepinephrine levels, then therapeutic effect is achieved, but toxic metabolites are formed causing side effects
Solution Approach 1:
The patent converts the harmful metabolic pathway into a beneficial outcome by deuterating the catechol ring positions that are normally sites of oxidative metabolism. The deuterium atoms slow down the formation of toxic quinone metabolites through the kinetic isotope effect, transforming a harmful metabolic process into a safer profile while preserving the therapeutic conversion of droxidopa to norepinephrine.
3Reliability
If droxidopa is given frequently to maintain norepinephrine levels, then therapeutic coverage is improved, but patient compliance deteriorates
Solution Approach 1:
By deuterating the droxidopa molecule, the patent changes the pharmacokinetic parameter of half-life from minutes to hours. This single parameter change enables once-daily or twice-daily dosing regimens, dramatically improving patient compliance while maintaining continuous therapeutic coverage of norepinephrine levels throughout the dosing interval.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The deuterated droxidopa compounds demonstrate enhanced pharmacokinetic and pharmacodynamic profiles, reducing toxicity and side effects, allowing for increased dosing intervals and improved efficacy in managing norepinephrine-related disorders.
Implementation Method 1
Deuterium (2H or D) is an isotope of hydrogen that has one neutron in its nucleus, whereas 1H has no neutrons. The carbon-deuterium (C-D) bond is stronger and breaks more slowly than the carbon-hydrogen (C-H) bond. This phenomenon is known as the kinetic isotope effect and is exploited in the compounds disclosed herein to slow down metabolism.
Implementation Method 2
Deuterium (2H or D) is an isotope of hydrogen that has one neutron in its nucleus, whereas 1H has no neutrons. The carbon-deuterium (C-D) bond is stronger and breaks more slowly than the carbon-hydrogen (C-H) bond. This phenomenon is known as the kinetic isotope effect and is exploited in the compounds disclosed herein to slow down metabolism.
Data Source
AI summary
The present invention relates to new dihydoxyphenyl modulators of neurotransmitter levels, pharmaceutical compositions thereof, and methods of use thereof.